Page 582 - Small Caps News Today

Orthocell identifying opportunities for expedited approval of CelGro after breakthrough results Orthocell Ltds (ASX:OCC) Paul Anderson caught up with Proactive soon after receiving positive results from a US 510(k) animal pilot study, indicating that CelGro® facilitates superior nerve regeneration when compared to the market-leading nerve repair device - restoring the sciatic nerve to a pre-injured state. As a result of this breakthrough nerve regeneration data, and in light of the previously...

Imugene has HER-Vaxx Phase 1B Data published in prestigious clinical cancer research journal HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The final PFS readout is expected within months. Imugene Ltd’s (ASX:IMU) (OTCMKTS:IUGNF) Phase 1b clinical trial data for its B cell peptide cancer immunotherapy HER-Vaxx has been published in the prestigious Am...

Antipa Minerals completes $22 million placement and launches $3 million SPP The company plans to use the proceeds from the capital raising to maintain its 35% interest in the Citadel Joint Venture with Rio Tinto and to accelerate exploration and appraisal activities at Minyari Dome Project. A share purchase plan (SPP) to raise up to A$3 million opens today. Antipa Minerals Ltd (ASX:AZY) has completed an institutional placement of more than 523.8 million shares at a price of A$0.42 ...

The process involves taking material from the ground and then purifying it in a bid to test it as the anode in a finished battery.

Jubilee Metals completes first phase of Project Roan on schedule CEO Leon Coetzer said the completion of phase 1 "is the first major step in our commitment to achieve our targeted production of 25,000 tonnes per annum of copper within the next four years" Jubilee Metals Group PLC (LON:JLP) said the first copper concentrate for refining at Jubilees Sable Refinery from Project Roan has been delivered on schedule. Project Roan is one of three locations where Jubilee plans to process copper and co...

Shield Therapeutics looks forward to US launch of Accrufer after transformational year Increasing sales in the US are estimated to turn the monthly cash flow positive between 15-18 months after launch Shield Therapeutics PLC (LON:STX) said it is now well placed for substantial future growth after a “transformational” year. The group said it is on track to launch its iron deficiency lead product Accrufer in the US by the end of June. Increasing sales in the US are estimated to turn the month...

Americans stuck at home are investing in their houses

All holes drilled in the Kate East zone have encountered “significantly higher” grade than the cut-off grade of 35 g/t silver used in the 2018 NI...

NA Proactive news snapshot: Zynerba Pharmaceuticals, Nerds On Site, Marvel Discovery, Water Tower Research UPDATE … A glance at some of the days highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psyc...

Drilling at the Hamilton Novo target south of the Machichie zone returned 3 metres at 13.2 g/t gold, including 1 metre at 36.7 g/t gold